anti-CD19 antibody-T-cell receptor-expressing T cells ET019003

A preparation of T lymphocytes that have been engineered by incorporating an as of yet undisclosed co-stimulatory molecule into T cells expressing an anti-CD19 antibody T-cell receptor (AbTCR) structure (ET190L1), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 AbTCR-expressing T cells ET019003 targets and binds to CD19-expressing tumor cells. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of CD19-positive tumor cells. The binding to CD19-expressing tumor cells may also activate the undisclosed costimulatory domain, leading to further T-cell proliferation. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. ET019003 is able to match the anticancer activity of chimeric antigen receptor (CAR) T cells, while they are less likely to stimulate cytokine release syndrome (CRS) and less likely to cause cytokine-related toxicities.